Press Release: OBIO CAAP Companies Raise More Than $109 Million in Investments
Ontario Bioscience Innovation Organization (OBIO®), a not-for-profit membership based organization that is Ontario’s leading advocate for the health science industry, announced today that Ontario health science companies that have participated in its Capital Access Advisory Program (CAAP®) have raised more than $109 Million since the CAAP program launched in 2013.
2018 OBIO Capital Access Advisory Program - Call for Applications
OBIO CAAP® is a unique, industry-led initiative that provides selected high-potential Ontario health science companies with mentoring, strategic guidance and access to an expansive network of health science industry experts and investors to enhance the ability of OBIO CAAP companies to secure financing.
Dose of the Valley 2018 - Call for Applications
DEADLINE TO APPLY: January 12, 2018
The Consulate General of Canada is accepting applications for their fourth annual Dose of the Valley program.
The two-day Life Sciences event includes roundtable discussions, industry-led workshops, one-on-one mentorship, an investor/partnering pitch session, and networking.
Springboard’s Health Innovation Hub: 2018 Applications Now Open
Springboard’s Health Innovation Hub is a program for women-led life science and digital health companies seeking seed and growth funding and expert connections. The program runs in two tracks: Life Science and Digital Health.
Selected companies will be matched with a team of relevant, targeted advisors and participate in several in-person and virtual workshops and presentation sessions throughout the year that provide exposure to influencers, active investors, and potential strategic partners.
New Funding Available: HealthBound II - Improve Patient Wait Times in an Outpatient Clinic at St. Michael's
The Biomedical Zone has opened up applications for HealthBound II, aimed at finding a solution to improve patient wait times in an outpatient clinic at St. Michael's.
- The winning company will receive:
- A cash prize of $5000
- Residency in the Biomedical Zone
- A subsidized pilot opportunity at St. Michael's
- Mentorship and immersion from clinicians, hospital administrators, and IT
Qvella Raises US$20M in Series B Financing to Fund Clinical Trials, On-Going Research, Team Expansion, and Manufacturing Buildup
December 4, 2017 – Qvella, a leading molecular diagnostics company closed US$20 million in Series B financing. The funding round was co-led by Qvella’s existing investor syndicate – including RA Capital, Whitecap Venture Partners, Hatteras Ventures, and Sands Capital – and new strategic investor bioMérieux, a world leader in the field of in vitro diagnostics. The proceeds will be used to fund clinical trials, to support on-going research and development, and to facilitate team expansion and manufacturing scale-up.
Thornhill Research & Rostrum Medical Announce Technology Development Agreement
TORONTO, ON Thornhill and Rostrum celebrate the finalization of a Technology Development Agreement which includes the licensing of certain Thornhill IP and an investment by Rostrum into Thornhill. This agreement is aimed to further Rostrum’s development of its Pulmonary Health Monitoring during ventilation, in ICU, OR and ER applications while supporting Thornhill’s commercialization efforts of their own innovative products.
Pre-CAAP Company: Iris Technologies Releases Powerful Testimonial Video
Iris Technologies, whose E-Paper screen technology reduces the negative health repercussions of using LCD screens for individuals recovering from a concussion, released a powerful testimonial video. David Goldband describes his experience with the product, and how it helped in his recovery.
OBIO 2017 Annual Public Meeting Features Dr. Edward Abrahams, President of the Personalized Medicine Coalition, and Launch of Latest Report, ‘Bridging the Talent Gap’
On November 27, 2017, OBIO hosted keynote speaker Dr. Edward Abrahams, President of the Personalized Medicine Coalition, at its 9th Annual Public Meeting at Norton Rose Fulbright LLP and launched OBIO's latest report, "Bridging the Talent Gap"
KalGene Pharmaceuticals Closes Financing to Support the Clinical Development of its Alzheimer's Therapeutic
TORONTO, ON KalGene Pharmaceuticals announced the closing of a Series A financing to support the advancement of its lead Alzheimer's therapeutic program. The syndicated investment was led by Lumira Capital and included participation from Anges Québec, Anges Québec Capital, Accel-Rx Health Sciences Accelerator and a number of Canadian family offices. In addition to the equity financing the company has also received significant financial support from leading Foundations focused on neurodegenerative diseases. Proceeds from these combined funding sources will support the development of KalGene's lead Alzheimer's therapeutic candidate.
New OBIO Report: Bridging the Talent Gap
On November 27th, as part of OBIO's Annual Public Meeting, OBIO will be launching our latest report, Bridging the Talent Gap, on the unique value of OBIO’s Health to Business Bridge (H2BB™) business internship program in 2017.
Ontario Announces Dr. Molly Shoichet As First Chief Scientist
Ontario has appointed Dr. Molly Shoichet as the province's first Chief Scientist with a mandate to advance science and innovation in Ontario. The new Office of the Chief Scientist will report to Reza Moridi, Minister of Research, Innovation and Science.
Dr. Shoichet is a professor at the University of Toronto, a member of the Order of Ontario, and founder of Hammock Therapeutics, an OBIO CAAP company.
CCAB Welcomes Mr. Robert Verhagen as New CEO
The Centre for the Commercialization of Antibodies and Biologics (CCAB) Board of Directors is pleased to announce the appointment of Mr. Robert Verhagen as the organization’s new Chief Executive Officer, effective November 1, 2017.
As CCAB’s new CEO, Mr. Verhagen will provide his strategic direction to position CCAB as a leader in the commercialization of academic discoveries in the biologics field and in the advancement of this biotech sector in Canada.
CAAP Company: Conavi Medical, China Grand Pharmaceutical & Healthcare Enter Distribution Agreement for Minimally Invasive Imaging Technologies in China
2015 CAAP Company Conavi Medical Inc., a privately-held company developing image guidance technologies for minimally invasive procedures announced that it has entered into an agreement with an affiliate of China Grand Pharmaceutical and Healthcare Holdings Limited (CG Healthcare) to serve as the exclusive distributor of its ForesightTM Intracardiac Echocardiography (ICE) and NovasightTM Hybrid Intravascular Imaging systems in China, Hong Kong, Taiwan and Macau.
Canadian Technology Accelerator (CTA) Initiative Accepting Applications - Spring 2018 Cohorts (February–June 2018)
Application Deadline January 10, 2018 - Apply Here
The Canadian Technology Accelerator Initiative (CTA) helps high-potential, high-growth Canadian technology SMEs seeking to expand to the U.S through a 5 month program of workshops, events, mentorship and business introductions.
Baylis Devices & Expanded Training Program: European Doctors Learn to Access the Heart from Any Approach
Baylis Medical Company Inc. has launched a hands-on workshop in Europe that will train cardiologists on innovative tools that enable access to the heart from any approach. This includes a growing number of procedures that require physicians to use major veins that feed into the heart from above.
Ontario Fall Economic Statement Analysis
On Tuesday, November 14, Ontario's Minister of Finance, Charles Sousa, delivered the government's Fall Economic Statement.
Coming up: Waterloo MedTech Conference
This year's conference will explore breaking down barriers to innovation within the healthcare ecosystem.
Call for Applications: Canada-Chicago Mentoring Program (C2MP)
The Trade Commissioner Service in partnership with the province of Ontario and the Chicago Innovation Mentors offers a tailor-made mentoring program focused on life sciences and healthcare innovators working in pharmaceuticals, health IT, and medical devices
Fundraising Event: Saving Sight in an Aging World
in support of research on the impact of Age-Related Macular Degeneration (AMD) by Dr. Shelley Boyd, CEO of Translatum Medicus.